Print

News

  • IGBA Statement // Solidarity Call to Action: To realize equitable global access to COVID-19 health technologies through sharing of knowledge, intellectual property and data (29 May 2020)

    “The International Generic and Biosimilar medicines Association (IGBA) invites generic and biosimilar medicines manufacturers to actively engage and commit to contributing to the global manufacturing capacity once an existing or newly-discovered therapeutic is proven to be effective against COVID-19. Read More
  • IGBA Pays Tribute to Bill Haddad (4 May 2020)

    IGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, today pays tribute to Bill Haddadi, who passed away last week. He was a pioneer in the development of generic medicine policy in Read More
  • ACCESS TO COVID-19 TOOLS (ACT) ACCELERATOR” - IGBA is Joining Forces on Global Collaboration to Overcome COVID-19 (24 April 2020)

    IGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, today endorses the commitment and call to action by an initial group of global health actors, private sector partners and other stakeholders, to Read More
  • IGBA Contributes to Global Discussion on Tailored Clinical Biosimilar Development with New Peer-Reviewed Scientific Paper (10 April 2020)

    The International Generic and Biosimilar medicines Association (IGBA), which represents global manufacturers of generic and biosimilar medicines, today announces the publication of its first peer-reviewed scientific paper on biosimilar medicines development: The Path Towards a Tailored Clinical Biosimilar Development (Biodrugs). Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14

Print

Vision and Mission

Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.

Print

The IGBA

In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.

The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. To reflect the evolving nature of the industry, in September 2015, IGPA incorporated under Swiss Law, and at the same time changed the name of the organization to the International Generic and Biosimilar Medicines Association (IGBA).

Annual Conference - Warsaw 2019

Annual Conference - Budapest 2018

Annual Conference - Lisboa 2017

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

C/O DYN SA
Rue de Cornavin 11
1201 Geneva, Switzerland

Telephone: +32 (0)2 5346607 (S. Kox)
E-mails: 
This email address is being protected from spambots. You need JavaScript enabled to view it.  
or  
Secretary General –   This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site